Is it possible to buy genuine Elafibranor in China?

Elafibranor (Elafibranor) is a new type of oral small molecule drug that belongs to PPARα/ Delta agonists are mainly used to treat liver diseases such as primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The drug has been verified by multiple clinical trials internationally and has shown good efficacy and safety, especially in improving liver function and reducing liver inflammation. However, irafibratenol has not yet been officially approved for marketing by the National Medical Products Administration (NMPA) in mainland China.

Since elafibratenol has not yet been approved in China, patients in mainland China cannot purchase genuine products of this drug through formal medical channels. Although some overseas channels such as pharmacies in Hong Kong, Taiwan or other countries may sell drugs, these informal channels have risks such as difficulty in ensuring the authenticity of the drugs and unclear transportation and storage conditions. In addition, drugs that have not been approved by regulatory authorities lack sufficient guarantees in terms of efficacy and safety, and there are great risks for patients to purchase and use them on their own.

For patients who rely on irafibratenol treatment, it is recommended to first consult a professional doctor to find out whether there are relevant clinical trial projects to participate in. Clinical trials can not only provide a formal source of drugs, but also obtain full monitoring by doctors to ensure drug safety and efficacy evaluation. At the same time, doctors will also recommend appropriate alternative therapies or supportive treatments based on the patient's specific situation to help patients better manage the disease.

Overall, as an emerging therapeutic drug, the launch of irafibratenol in mainland China still needs to wait for official approval and further improvement of related research. Patients should avoid purchasing through informal channels to avoid health risks caused by improper drug quality or use. Actively paying attention to the latest news from the national drug regulatory authorities and cooperating with the doctor's treatment plan are the correct ways to ensure treatment effectiveness and safety.

Reference materials:https://www.drugs.com/